{"prompt": "['Trelagliptin-4002', 'Page 8 of 66', 'Version 1.0', 'November 2, 2016', '13.1.2 Analysis of demographic and other baseline characteristics', '55', '13.1.3 Efficacy analysis', '55', '13.1.4 Safety analysis', '57', '13.2', 'Criteria for interim analysis and premature discontinuation', '57', '13.3', 'Determination of the number of planned study subject', '57', '14.0', 'QUALITY CONTROL AND QUALITY ASSURANCE', '59', '14.1', 'Monitoring of the study site', '59', '14.2', 'Deviation from the Ethical Guidelines for Medical and Health Research', 'Involving Human Subjects and the study protocol', '59', '14.3', 'Quality assurance audits and regulatory agency inspections', '59', '15.0', 'ETHICAL CONDUCT OF CLINICAL STUDY', '61', '15.1', 'Approval of the Ethical Review Board, etc.', '61', '15.2', 'Conflict of interest', '62', '15.3', 'Informed consent form and information sheet, and the agreement of the', 'study subjects', '62', '15.4', 'Personal information of the study subjects', '63', '15.5', 'Consultation windows for the study subjects or persons related to the', 'study concerned', '63', '15.6', 'Financial burden or reward to the study subjects', '63', '15.7', 'Benefits and inconveniences to the study subjects', '64', '15.7.1 Benefits to study subjects', '64', '15.7.2 Inconveniences to study subjects', '64', '15.8 Attribution of study results and access rights', '64', '15.8.1 Attribution of study results', '64', '15.8.2 Data access rights', '64', '15.9 Reporting of results, publication, disclosure, and clinical study', 'registration policy', '64', '15.9.1 Reporting of results, publication and disclosure', '64', '15.9.2 Clinical study registration', '65', '15.9.3 Clinical trial results disclosure', '65', '15.10 Insurance and compensation for injury', '65', '16.0 REFERENCES', '66', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 9 of 66', 'Version 1.0', 'November 2, 2016', 'LIST OF IN-TEXT TABLES', 'Table 8.a', 'Daily DPP-4 inhibitor', '32', 'Table 9.a', 'Laboratory tests', '36', 'Table 10.a', 'Takeda Medically Significant AE List', '45', 'LIST OF IN-TEXT FIGURES', 'Figure 6.a', 'Outline of the clinical study design', '24', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 10 of 66', 'Version 1.0', 'November 2, 2016', '2.0', 'STUDY SUMMARY', 'Sponsor:', 'Study drug:', 'Takeda Pharmaceutical Company Limited', 'Trelagliptin', 'Study title:', 'Study of the QOL evaluation of Trelagliptin in patients with type 2 diabetes mellitus', 'Protocol number: Trelagliptin-4002', 'Clinical study design:', 'This is a multi-center, randomized, open-label, parallel-group comparison study to assess the', 'reduction in treatment burden during the administration of a DPP-4 inhibitor (trelagliptin or a daily', 'DPP-4 inhibitor) for 12 weeks in patients with type 2 diabetes on diet and exercise therapy only.', 'Subjects who are determined to be eligible based on the results of eligibility assessment after', 'informed consent has been obtained will be randomized to either the study drug (trelagliptin) group', 'or the comparative drug (daily DPP-4 inhibitor) group. Randomization was stratified by the total', 'score (<80% (score 139.4), >80% (score 139.4)*) for total score of the \"Diabetes Therapy-Related', 'QOL (DTR-QOL) Questionnaire\" and \"HbAlc (<8.0%, 8.0%)\" at the start of the screening period.', '* A scale of 1 to 7 with 7 as the best was used for each QOL question item, and total score', 'calculated by adding up scores of each question was expressed as a percentage of the maximum total', 'score (i.e., the best score [203] = 100%; the worst score [29] = 0%.)', 'Objectives:', 'The objective is to assess the reduction in treatment burden during 12 weeks of trelagliptin', 'administration in patients with type 2 diabetes on diet and exercise therapy only', 'Subjects:', 'Patients with type 2 diabetes on diet and exercise therapy alone', 'Planned number of study subjects:', 'Number of study sites:', 'As the number of randomized subjects:', 'Approximately 15', 'The study drug (Trelagliptin) group 120 subjects', 'The comparative drug (daily DPP-4 inhibitor) group', '120 subjects', 'Dose and method of administration:', 'Route of administration:', 'The study drug (Trelagliptin) group: Trelagliptin 100', 'Oral', 'mg is orally administered once weekly. Trelagliptin', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 11 of 66', 'Version 1.0', 'November 2, 2016', '50 mg is orally administered once weekly in patients', 'with moderate renal impairment.', 'The comparative drug (Daily DPP-4 inhibitor) group:', 'An inhibitor is orally administered at the dosage and', 'administration in the package inserts for each drug.', 'Duration of treatment:', 'Duration of evaluation:', '12 weeks', '16 weeks', '(Screening period: 4 weeks; treatment', 'period: 12 weeks)', 'Inclusion criteria:', 'Eligibility of study subjects shall be determined in accordance with the following criteria.', '1.', 'Patients diagnosed as type 2 diabetes.', '2.', 'Patients with a stable diet and exercise therapy only for at least 12 weeks prior to the start of the', 'screening period.', '3.', 'Patients who require a DPP-4 inhibitor treatment.', '4.', 'Patients with and <10.0 % at the start of the screening period.', '5. Patients who completed DTR-QOL questionnaire at the start of the screening period.', '6.', 'Patients who have receive less than 2 types of medication for treatment of comorbidities (such', 'as hypertension or dyslipidemia) at the start of the screening period (any number of daily', 'doses).', '7.', 'Patients who, in the opinion of the principal investigator or the investigator, are capable of', 'understanding the content of the clinical study and complying with the study protocol', 'requirements.', '8. Patients who can provide the written informed consent prior to the initiation of any study', 'procedures.', '9.', 'Patients aged >20 years at the time of informed consent.', '10. Outpatient.', 'Exclusion criteria:', 'Study subjects meeting any of the criteria below shall not be included in this study.', '1.', 'Patients who are receiving any oral anti-diabetic medication for the treatment of type 2 diabetes', 'at the start of the screening period.', '2.', 'Patients diagnosed as type 1 diabetes.', 'CONFIDENTIAL']", "completion": ""}